MX2023012902A - Proteinas de union a antigenos que se unen especificamente a prame. - Google Patents

Proteinas de union a antigenos que se unen especificamente a prame.

Info

Publication number
MX2023012902A
MX2023012902A MX2023012902A MX2023012902A MX2023012902A MX 2023012902 A MX2023012902 A MX 2023012902A MX 2023012902 A MX2023012902 A MX 2023012902A MX 2023012902 A MX2023012902 A MX 2023012902A MX 2023012902 A MX2023012902 A MX 2023012902A
Authority
MX
Mexico
Prior art keywords
antigen binding
binding proteins
prame
antigen
nucleic acids
Prior art date
Application number
MX2023012902A
Other languages
English (en)
Inventor
Sebastian Bunk
Frank SCHWÖBEL
Claudia Wagner
Heiko Schuster
Dominik Maurer
Felix Unverdorben
Meike Hutt
Martin Hofmann
Gabriele Pszolla
Florian Schwörer
Maike Jaworski
Original Assignee
Immatics Biotechnologies Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Immatics Biotechnologies Gmbh filed Critical Immatics Biotechnologies Gmbh
Publication of MX2023012902A publication Critical patent/MX2023012902A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001184—Cancer testis antigens, e.g. SSX, BAGE, GAGE or SAGE
    • A61K39/001189—PRAME
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Cell Biology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Mycology (AREA)
  • Oncology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

La presente invención se refiere a proteínas de unión a antígeno dirigidas contra antígenos derivados de la proteína PRAME. La invención en particular proporciona proteínas de unión a antígeno que son específicas para el antígeno expresado por el tumor PRAME, donde el antígeno tumoral comprende o que consiste en la SEQ ID NO: 50 y está en un complejo con una proteína del complejo mayor de histocompatibilidad (MHC) proteína. Las proteínas de unión a antígeno de la invención contienen, en particular, las regiones determinantes complementarias (CDR) de nuevos receptores de células T (TCR) diseñados que se unen específicamente a dicho péptido PRAME. Las proteínas de unión a antígeno de la invención son para su uso en el diagnóstico, tratamiento y prevención de enfermedades cancerosas que expresan PRAME. Da a conocer además ácidos nucleicos que codifican las proteínas de unión a antígeno de la invención, vectores que comprenden dichos ácidos nucleicos, células recombinantes que expresan las proteínas de unión a antígeno y composiciones farmacéuticas que comprenden las proteínas de unión a antígeno de la invención.
MX2023012902A 2021-05-05 2022-05-04 Proteinas de union a antigenos que se unen especificamente a prame. MX2023012902A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163184689P 2021-05-05 2021-05-05
EP21172351 2021-05-05
PCT/EP2022/062017 WO2022233956A1 (en) 2021-05-05 2022-05-04 Antigen binding proteins specifically binding prame

Publications (1)

Publication Number Publication Date
MX2023012902A true MX2023012902A (es) 2023-11-08

Family

ID=81579586

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2023012902A MX2023012902A (es) 2021-05-05 2022-05-04 Proteinas de union a antigenos que se unen especificamente a prame.

Country Status (14)

Country Link
US (4) US12570760B2 (es)
EP (1) EP4334361A1 (es)
JP (1) JP2024518378A (es)
KR (1) KR20240004935A (es)
AU (1) AU2022270361A1 (es)
BR (1) BR112023022765A2 (es)
CA (1) CA3217738A1 (es)
CL (1) CL2023003232A1 (es)
CO (1) CO2023014722A2 (es)
IL (1) IL308257A (es)
MX (1) MX2023012902A (es)
PE (1) PE20242343A1 (es)
TW (1) TW202309071A (es)
WO (1) WO2022233956A1 (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116554328B (zh) * 2023-05-11 2023-09-29 皖南医学院第一附属医院（皖南医学院弋矶山医院） 一种靶向trbv12的单链抗体、car、car-nk细胞及应用
CN118221811B (zh) * 2023-08-25 2025-05-30 立凌生物制药(苏州)有限公司 靶向prame多肽的单域抗体及其用途
WO2025137640A1 (en) 2023-12-22 2025-06-26 Gilead Sciences, Inc. Azaspiro wrn inhibitors
WO2025233431A1 (en) 2024-05-07 2025-11-13 Immatics Biotechnologies Gmbh Heteromeric proteins comprising three heteromerization improving substitution, production, combinations and applications thereof
GB2641580A (en) 2024-06-07 2025-12-10 T Therapeutics Ltd Tumour-transforming multispecific proteins
WO2026008886A1 (en) 2024-07-05 2026-01-08 Immatics Biotechnologies Gmbh Means and methods for the quantification of target expression
WO2026078231A1 (en) 2024-10-11 2026-04-16 T-Therapeutics Limited Soluble non-aggregating immune ligand
CN119529098B (zh) * 2025-01-22 2025-05-30 北京可瑞生物科技有限公司 对mage-a1具有特异性的结合分子和抗cd3的融合蛋白

Family Cites Families (174)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5204A (en) 1847-07-24 james cantelo
US244A (en) 1837-06-30 Edward flint
WO1981001145A1 (en) 1979-10-18 1981-04-30 Univ Illinois Hydrolytic enzyme-activatible pro-drugs
US4861719A (en) 1986-04-25 1989-08-29 Fred Hutchinson Cancer Research Center DNA constructs for retrovirus packaging cell lines
GB8705477D0 (en) 1987-03-09 1987-04-15 Carlton Med Prod Drug delivery systems
US4975278A (en) 1988-02-26 1990-12-04 Bristol-Myers Company Antibody-enzyme conjugates in combination with prodrugs for the delivery of cytotoxic agents to tumor cells
US5202238A (en) 1987-10-27 1993-04-13 Oncogen Production of chimeric antibodies by homologous recombination
US5278056A (en) 1988-02-05 1994-01-11 The Trustees Of Columbia University In The City Of New York Retroviral packaging cell lines and process of using same
US5208020A (en) 1989-10-25 1993-05-04 Immunogen Inc. Cytotoxic agents comprising maytansinoids and their therapeutic use
US5670488A (en) 1992-12-03 1997-09-23 Genzyme Corporation Adenovirus vector for gene therapy
IL104570A0 (en) 1992-03-18 1993-05-13 Yeda Res & Dev Chimeric genes and cells transformed therewith
US8211422B2 (en) 1992-03-18 2012-07-03 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Chimeric receptor genes and cells transformed therewith
DE69434860T2 (de) 1993-02-22 2007-03-15 The Rockefeller University Herstellung von helfer-freien retroviren mit hohem titer mittels transienter transfektion
FR2712812B1 (fr) 1993-11-23 1996-02-09 Centre Nat Rech Scient Composition pour la production de produits thérapeutiques in vivo.
PT1231268E (pt) 1994-01-31 2005-11-30 Univ Boston Bancos de anticorpos policlonais
IL116816A (en) 1995-01-20 2003-05-29 Rhone Poulenc Rorer Sa Cell for the production of a defective recombinant adenovirus or an adeno-associated virus and the various uses thereof
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
CN1241944C (zh) 1995-09-11 2006-02-15 协和发酵工业株式会社 抗人白介素－5受体α链的抗体
US6013516A (en) 1995-10-06 2000-01-11 The Salk Institute For Biological Studies Vector and method of use for nucleic acid delivery to non-dividing cells
ES2203782T3 (es) 1996-01-17 2004-04-16 Imperial College Innovations Limited Inmunoterapia que utiliza linfocitos t citotoxicos (ctl).
GB9809951D0 (en) 1998-05-08 1998-07-08 Univ Cambridge Tech Binding molecules
JP4972264B2 (ja) 1999-12-06 2012-07-11 ボード オブ トラスティーズ オブ ザ ユニバーシティ オブ イリノイ 高親和性ｔｃｒタンパク質および方法
AU2002321581C1 (en) 2001-08-31 2008-09-18 Adaptimmune Limited Soluble T cell receptor
DK1438400T3 (da) 2001-10-01 2009-10-05 Dyax Corp Flerkædede eukaryote display-vektorer og anvendelser deraf
DE10225139A1 (de) 2002-05-29 2004-02-26 Immatics Biotechnologies Gmbh Verfahren zur Identifizierung von immunreaktiven Peptiden
DE60327795D1 (de) 2002-11-09 2009-07-09 Immunocore Ltd T zell rezeptor "display"
GB0308731D0 (en) 2003-04-15 2003-05-21 Anticancer Therapeutic Inv Sa Method of radiotherapy
JP2007519910A (ja) 2004-01-28 2007-07-19 イマティクス バイオテクノロジーズ ゲーエムベーハー 腫瘍関連ペプチドの同定および定量方法
US20080206270A1 (en) 2004-07-08 2008-08-28 Minev Boris R Enhancing Class I Antigen Presentation With Synthetic Sequences
PL2002003T3 (pl) 2005-05-27 2016-06-30 Ospedale San Raffaele Srl Wektor genetyczny zawierający mi-RNA
MX2007015933A (es) 2005-06-17 2008-04-21 Mannkind Corp Metodos y composiciones para generar respuestas inmunes multivalentes contra espitopes dominantes y subdominantes, expresados en celulas cancerigenas y estromas tumorales.
CN101687020A (zh) 2005-06-17 2010-03-31 曼康公司 用于癌症的多价引发-和-增强免疫治疗剂
NZ564359A (en) 2005-06-17 2011-09-30 Mannkind Corp Analogs of pepetides corresponding to class I MHC-restricted T cell epitopes
US20110245153A1 (en) 2006-03-15 2011-10-06 National Institutes of Health (NIH), U. S. Dept. of Health and Human Resources (DHHS) U. S. Govt. Neutralizing Agents for Bacterial Toxins
AT503861B1 (de) 2006-07-05 2008-06-15 F Star Biotech Forsch & Entw Verfahren zur manipulation von t-zell-rezeptoren
WO2008039818A2 (en) 2006-09-26 2008-04-03 Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services Modified t cell receptors and related materials and methods
CA2665568C (en) 2006-10-04 2018-01-09 Janssen Pharmaceutica, N.V. Preparation of inactivated artificial antigen presenting cells and their use in cell therapies
US20100105136A1 (en) 2006-10-09 2010-04-29 The General Hospital Corporation Chimeric t-cell receptors and t-cells targeting egfrviii on tumors
PT2114993E (pt) 2007-01-15 2012-11-28 Glaxosmithkline Biolog Sa Vacina
EP3173480A3 (en) 2007-03-05 2017-08-16 International Institute of Cancer Immunology, Inc. Cancer antigen-specific t-cell receptor gene, peptide encoded by the gene, and use of them
US20110045007A1 (en) 2007-05-31 2011-02-24 Genmab A/S Fusion or linked proteins with extended half life
US20100297093A1 (en) 2007-09-25 2010-11-25 The United States Of America, As Represented By The Secretary, Department Of Health And Human Modified t cell receptors and related materials and methods
CA2711806A1 (en) 2008-01-11 2009-07-16 Morphosys Ag Display vectors and methods and uses thereof
US9840695B2 (en) 2009-04-28 2017-12-12 Agriculture Victoria Services Pty Ltd Plant technology
EP2258719A1 (en) 2009-05-19 2010-12-08 Max-Delbrück-Centrum für Molekulare Medizin (MDC) Multiple target T cell receptor
US8465743B2 (en) 2009-10-01 2013-06-18 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Anti-vascular endothelial growth factor receptor-2 chimeric antigen receptors and use of same for the treatment of cancer
CA2777053A1 (en) 2009-10-06 2011-04-14 The Board Of Trustees Of The University Of Illinois Human single-chain t cell receptors
US20130129723A1 (en) 2009-12-29 2013-05-23 Emergent Product Development Seattle, Llc Heterodimer Binding Proteins and Uses Thereof
CN102958942A (zh) 2009-12-29 2013-03-06 新兴产品开发西雅图有限公司 异二聚体结合蛋白及其应用
WO2011085178A1 (en) 2010-01-11 2011-07-14 Trustees Of Dartmouth College Monomeric bi-specific fusion protein
GB201006360D0 (en) 2010-04-16 2010-06-02 Immatics Biotechnologies Gmbh Method for differentially quantifying naturally processed HLA-restricted peptides for cancer, autoimmune and infectious diseases immunotherapy development
WO2011140284A2 (en) 2010-05-04 2011-11-10 Fred Hutchinson Cancer Research Center Conditional superagonist ctl ligands for the promotion of tumor-specific ctl responses
SG193023A1 (en) 2011-02-11 2013-10-30 Sloan Kettering Inst Cancer Hla-restricted, peptide-specific antigen binding proteins
TWI588156B (zh) 2011-03-28 2017-06-21 賽諾菲公司 具有交叉結合區定向之雙重可變區類抗體結合蛋白
KR20140039318A (ko) 2011-06-28 2014-04-01 인터내셔널 인스티튜트 오브 캔서 이무놀로지 인코퍼레이티드 펩티드 암 항원 특이적 ｔ 세포의 리셉터 유전자
WO2013041865A1 (en) 2011-09-22 2013-03-28 Immunocore Limited T cell receptors
AU2013295652B2 (en) 2012-07-27 2018-02-08 The Board Of Trustees Of The University Of Illinois Engineering T-cell receptors
CA2893918C (en) 2012-12-06 2020-11-24 Callaghan Innovation Research Limited Conjugate compounds
AU2013204922B2 (en) 2012-12-20 2015-05-14 Celgene Corporation Chimeric antigen receptors
CN105339498A (zh) 2013-03-07 2016-02-17 贝勒医学院 癌症中靶向cd138
AU2014236769B2 (en) 2013-03-15 2018-09-27 Amgen Inc. Heterodimeric bispecific antibodies
GB201314404D0 (en) 2013-08-12 2013-09-25 Immunocore Ltd T Cell Receptors
TR201907352T4 (tr) 2014-03-25 2019-06-21 Merial Inc Atenüe edi̇lmi̇ş histophilus somni i̇çeren i̇mmünoloji̇k bi̇leşi̇mler
IL290655B2 (en) 2014-05-29 2024-05-01 Us Health Anti-human papillomavirus 16 E7 T-cell chelates
SI3151672T1 (sl) 2014-06-06 2021-03-31 Bluebird Bio, Inc. Izboljšani T-celični sestavki
MX2017001079A (es) 2014-07-24 2017-09-12 Bluebird Bio Inc Receptores de antígeno quiméricos de antígeno de maduración de células b (bcma).
CA2958200A1 (en) 2014-08-14 2016-02-18 Novartis Ag Treatment of cancer using a gfr alpha-4 chimeric antigen receptor
GB201423361D0 (en) 2014-12-30 2015-02-11 Immatics Biotechnologies Gmbh Method for the absolute Quantification of naturally processed HLA-Restricted cancer peptides
CR20170383A (es) 2015-01-23 2017-11-22 Sanofi Sa Anticuerpos anti-cd3, anticuerpos anti-cd-123 y anticuerpos biespecíficos que se unen específicamente a cd3 y/o cd123
JP2018510627A (ja) 2015-03-10 2018-04-19 レイデン ユニバーシティ メディカル センター メラノーマ優先発現抗原に対して向けられたｔ細胞レセプターおよびその使用
US10744157B2 (en) 2015-03-26 2020-08-18 The Trustees Of Dartmouth College Anti-MICA antigen binding fragments, fusion molecules, cells which express and methods of using
GB201506642D0 (en) 2015-04-20 2015-06-03 Ucl Business Plc T cell receptor
WO2016174652A1 (en) 2015-04-30 2016-11-03 Technion Research & Development Foundation Limited Chimeric antigen receptors and methods of their use
US10544392B2 (en) 2015-05-01 2020-01-28 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Methods of isolating T cells and T cell receptors having antigenic specificity for a cancer-specific mutation from peripheral blood
CN107995913B (zh) 2015-05-18 2022-02-11 T细胞受体治疗公司 使用融合蛋白对tcr重编程的组合物和方法
TW201702272A (zh) 2015-05-22 2017-01-16 美國紀念斯隆 凱特琳癌症中心 Ｐｒａｍｅ肽專一性類ｔ細胞受體抗體
LT3353212T (lt) 2015-09-23 2021-12-27 Regeneron Pharmaceuticals, Inc. Optimizuoti anti-cd3 bispecifiniai antikūnai ir jų naudojimas
US11047011B2 (en) 2015-09-29 2021-06-29 iRepertoire, Inc. Immunorepertoire normality assessment method and its use
WO2017059900A1 (en) 2015-10-07 2017-04-13 Biontech Cell & Gene Therapies Gmbh Antigen receptors and uses thereof
EP3842450A1 (en) 2015-10-23 2021-06-30 Eureka Therapeutics, Inc. Antibody/t-cell receptor chimeric constructs and uses thereof
MX2018005618A (es) 2015-11-05 2018-08-01 Juno Therapeutics Inc Receptores quimericos que contienen dominios inductores de traf y composiciones y metodos relacionados.
GB201522592D0 (en) 2015-12-22 2016-02-03 Immunocore Ltd T cell receptors
US11034767B2 (en) 2016-04-15 2021-06-15 Trustees Of Dartmouth College High affinity B7-H6 antibodies and antibody fragments
EP3472208B9 (en) 2016-06-17 2023-10-04 Medigene Immunotherapies GmbH T cell receptors and uses thereof
EP3475938B1 (en) 2016-06-27 2020-12-23 The Procter and Gamble Company Apparatus and method for assessing tooth-sensitivity treatment by oral-care product
EP3494138A1 (en) 2016-08-02 2019-06-12 TCR2 Therapeutics Inc. Compositions and methods for tcr reprogramming using fusion proteins
WO2018026691A1 (en) 2016-08-02 2018-02-08 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Anti-kras-g12d t cell receptors
WO2018026018A1 (ja) 2016-08-05 2018-02-08 国立大学法人東北大学 Ｔ細胞受容体の認識機構を用いたがん又は感染症の治療及び診断
SG11201901642XA (en) 2016-08-26 2019-03-28 Baylor College Medicine Constitutively active cytokine receptors for cell therapy
US11453726B2 (en) 2016-09-15 2022-09-27 Quadrucept Bio Limited Multimers, tetramers and octamers
CN110139873A (zh) 2016-10-03 2019-08-16 朱诺治疗学股份有限公司 Hpv特异性结合分子
GB201617714D0 (en) 2016-10-19 2016-11-30 Ucl Business Plc T Cell receptor
GB201617716D0 (en) 2016-10-19 2016-11-30 Ucl Business Plc Cell
DE102016121899A1 (de) 2016-11-15 2018-05-17 Immatics Biotechnologies Gmbh Verfahren zur Herstellung von elektrokompetenten Hefezellen und Verfahren zur Verwendung dieser Zellen
DE102016123893A1 (de) 2016-12-08 2018-06-14 Immatics Biotechnologies Gmbh T-Zellrezeptoren mit verbesserter Bindung
US11236145B2 (en) 2017-03-23 2022-02-01 Immatics Biotechnologies Gmbh T cell receptors and immune therapy using the same against PRAME positive cancers
DE102017106305A1 (de) 2017-03-23 2018-09-27 Immatics Biotechnologies Gmbh Neue T-Zellrezeptoren und deren Verwendung in Immuntherapien gegen prame-positive Krebsarten
CA3059769A1 (en) 2017-04-28 2018-11-01 Elstar Therapeutics, Inc. Multispecific molecules comprising a non-immunoglobulin heterodimerization domain and uses thereof
CN111094333A (zh) 2017-06-01 2020-05-01 斯图加特大学 异源二聚化的Ig结构域
GB201709866D0 (en) 2017-06-20 2017-08-02 Immunocore Ltd T cell receptors
RU2020103379A (ru) 2017-07-04 2021-08-04 Куревак Аг Новые молекулы нуклеиновых кислот
SG11202000025SA (en) 2017-07-14 2020-02-27 Immatics Biotechnologies Gmbh Improved dual specificity polypeptide molecule
CN109468278A (zh) 2017-09-08 2019-03-15 科济生物医药（上海）有限公司 基因工程化的t细胞及应用
AU2018337960B2 (en) 2017-09-20 2025-08-14 Neximmune, Inc. Cell compositions comprising antigen-specific T cells for adoptive therapy
CN117843810A (zh) 2017-09-22 2024-04-09 上海药明生物技术有限公司 新型双特异性多肽复合物
TWI687227B (zh) 2017-10-03 2020-03-11 生倍科技股份有限公司 用於t細胞免疫療法之組合及其用途
BR112020006643A2 (pt) 2017-10-03 2020-09-24 Juno Therapeutics Inc moléculas de ligação específica ao hpv
EP3697438A4 (en) 2017-10-18 2021-08-18 Intrexon Corporation POLYPEPTIDE COMPOSITIONS WITH SPACERS
SG11202006050XA (en) 2017-12-29 2020-07-29 Memorial Sloan Kettering Cancer Center Enhanced chimeric antigen receptors and uses thereof
JPWO2019151392A1 (ja) 2018-01-31 2021-02-04 国立大学法人東北大学 抗原特異的ｍｈｃ発現調節法
CA3090791A1 (en) 2018-02-11 2019-08-15 Memorial Sloan-Kettering Cancer Center Non-hla restricted t cell receptors and uses thereof
CN110156889B (zh) 2018-02-14 2023-03-10 中国科学院广州生物医药与健康研究院 高亲和力HBs T细胞受体
CA3094468A1 (en) 2018-04-05 2019-10-10 Juno Therapeutics, Inc. Methods of producing cells expressing a recombinant receptor and related compositions
MX2020011023A (es) 2018-04-19 2021-01-29 Baylor College Medicine Reprogramación de células t cd4 en células cd8 citotóxicas por expresión forzada de cd8ab y receptores de células t restringidos de clase 1.
MX2020012124A (es) 2018-05-14 2021-04-19 Immunocore Ltd Polipeptidos de unión bifuncional.
EA202091977A1 (ru) 2018-05-28 2021-02-09 Драгонфлай Терапьютикс, Инк. Мультиспецифические связывающие белки, которые связывают cd33, nkg2d и cd16, и способы применения
EP3818083A2 (en) 2018-07-03 2021-05-12 Elstar Therapeutics, Inc. Anti-tcr antibody molecules and uses thereof
US20220275043A1 (en) 2018-07-17 2022-09-01 Massachusetts Institute Of Technology Soluble multimeric immunoglobulin-scaffold based fusion proteins and uses thereof
CN112912494B (zh) 2018-07-26 2024-12-17 耶稣圣婴儿童医院 γ-δT细胞和自然杀伤细胞的治疗制剂以及制造和使用方法
KR20210086612A (ko) 2018-09-04 2021-07-08 트레오스 바이오 리미티드 펩타이드 백신
WO2020057610A1 (en) 2018-09-20 2020-03-26 Wuxi Biologics (Shanghai) Co., Ltd. Novel bispecific anti-ctla-4/pd-1 polypeptide complexes
WO2020081537A1 (en) 2018-10-16 2020-04-23 Texas Tech University System Method to express, purify, and biotinylate eukaryotic cell-derived major histocompatibility complexes
AU2019375997A1 (en) 2018-11-08 2021-06-03 Neximmune, Inc. T cell compositions with improved phenotypic properties
WO2020118094A1 (en) 2018-12-06 2020-06-11 Guangdong Tcrcure Biopharma Technology Co., Ltd. Combinational tcr-t cell therapy targeting tumor antigens, tgf-beta, and immune checkpoints
WO2020123938A1 (en) 2018-12-14 2020-06-18 Bluebird Bio, Inc. Dimerizing agent regulated immunoreceptor complexes
CA3126064A1 (en) 2019-01-07 2020-07-16 Children's National Medical Center Improved targeted t-cell therapy for treatment of multiple myeloma
US12448429B2 (en) 2019-03-06 2025-10-21 Dana-Farber Cancer Institute, Inc. T cell receptors specific to b-cell maturation antigen for treatment of cancer
US12018061B2 (en) 2019-03-08 2024-06-25 St Phi Therapeutics Co., Ltd. Chimeric endocytic receptors and method of use thereof
US20220153863A1 (en) 2019-03-13 2022-05-19 Hans David Staffan Ulmert Prame binding molecules and uses thereof
WO2020186158A2 (en) 2019-03-13 2020-09-17 Ulmert Hans David Staffan Prame binding molecules and uses thereof
GB201903767D0 (en) 2019-03-19 2019-05-01 Quadrucept Bio Ltd Multimers, tetramers & octamers
EP3941490A4 (en) 2019-03-20 2023-01-04 2seventy bio, Inc. ADOPTIVE CELLULAR THERAPY
EP3959307A4 (en) 2019-04-22 2023-08-23 Nanjing Legend Biotech Co., Ltd. Engineered cells and uses thereof
GB201906685D0 (en) 2019-05-13 2019-06-26 Ultrahuman Six Ltd Activatable protein constructs and uses thereof
WO2020243134A1 (en) 2019-05-27 2020-12-03 Immatics US, Inc. Viral vectors and their use in adoptive cellular therapy
MX2022000667A (es) 2019-07-15 2022-07-21 Neogene Therapeutics B V Metodo para aislar genes tcr.
CA3148072A1 (en) 2019-07-19 2021-01-28 Memorial Sloan-Kettering Cancer Center Fusion polypeptide for immunotherapy
CN114555644A (zh) 2019-07-23 2022-05-27 德国癌症研究中心 用于治疗aml的多肽
WO2021016609A1 (en) 2019-07-24 2021-01-28 Eureka Therapeutics, Inc. Cells expressing chimeric antigen receptors and chimeric stimulating receptors and uses thereof
DE102019121007A1 (de) 2019-08-02 2021-02-04 Immatics Biotechnologies Gmbh Antigenbindende Proteine, die spezifisch an MAGE-A binden
GB201911286D0 (en) 2019-08-07 2019-09-18 Ucl Business Plc Method
EP4025598A1 (en) 2019-09-06 2022-07-13 Eli Lilly and Company Proteins comprising t-cell receptor constant domains
US20220396635A1 (en) 2019-09-25 2022-12-15 Universität Stuttgart Trivalent binding molecules
EP4034570A4 (en) 2019-09-27 2023-10-25 Agenus Inc. HETERODIMERIC PROTEINS
US20210147929A1 (en) 2019-10-11 2021-05-20 Saint Louis University Immune receptor analysis as diagnostic assay
GB201915282D0 (en) 2019-10-22 2019-12-04 Immunocore Ltd Specific binding molecules
AU2020384374A1 (en) 2019-11-15 2022-06-09 Seattle Project Corp. Antigen-binding proteins targeting shared neoantigens
EP4061827A1 (en) 2019-11-18 2022-09-28 BioNTech SE Prame tcr receptors and uses thereof
EP4077370A4 (en) 2019-12-17 2024-02-28 The Johns Hopkins University MANABODIES TARGETING TUMOR ANTIGENS AND METHODS OF USE
CN110964122B (zh) 2019-12-24 2022-04-15 南京北恒生物科技有限公司 T细胞受体融合蛋白及其用途
EP4103233A4 (en) 2020-02-14 2025-03-26 Epivax, Inc. T-CELL EPITOPES AND ASSOCIATED COMPOSITIONS FOR THE PREVENTION, DIAGNOSIS AND TREATMENT OF COVID-19
AU2021220957A1 (en) 2020-02-14 2022-09-01 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services HLA class I-restricted T cell receptors against ras with G12V mutation
TWI900533B (zh) 2020-02-26 2025-10-11 美國衛生與公眾服務部 針對含有ｇ１２ｖ突變之ｒａｓ之ｈｌａ第ｉｉ類限制性ｔ細胞受體
DE102020106710A1 (de) 2020-03-11 2021-09-16 Immatics US, Inc. Wpre-mutantenkonstrukte, zusammensetzungen und zugehörige verfahren
DE102020111571A1 (de) 2020-03-11 2021-09-16 Immatics US, Inc. Wpre-mutantenkonstrukte, zusammensetzungen und zugehörige verfahren
JP2023518049A (ja) 2020-03-16 2023-04-27 ユニバーシティ オブ サザン カリフォルニア 新規な抗原結合ドメインおよびそれを組み込んだ合成抗原受容体
US20230130925A1 (en) 2020-03-16 2023-04-27 University Of Southern California Methods to prevent, ameliorate and treat complications from viral infections
WO2021211455A1 (en) 2020-04-13 2021-10-21 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Hla class i-restricted t cell receptors against lmp2
WO2021222576A1 (en) 2020-05-01 2021-11-04 A2 Biotherapeutics, Inc. Pag1 fusion proteins and methods of making and using same
AU2021289612A1 (en) 2020-06-10 2023-01-19 The University Of Melbourne HIV-1 antibodies
GB202010329D0 (en) 2020-07-06 2020-08-19 Immunocore Ltd Specific binding molecules
AU2021311470A1 (en) 2020-07-24 2023-02-02 Ahs Hospital Corp. Binding proteins recognizing SARS-CoV-2 antigens and uses thereof
EP4188416A4 (en) 2020-07-27 2024-08-21 Arizona Board of Regents on behalf of the University of Arizona MULTIFUNCTIONAL IMMUNOGLOBULIN-FOLDED POLYPEPTIDES FROM SUBSTITUTION TRANSLATIONAL INITIATION AND TERMINATION
TW202227616A (zh) 2020-08-21 2022-07-16 美商英麥提克斯股份有限公司 分離ｃｄ８＋選擇ｔ細胞的方法
US20230374140A1 (en) 2020-10-09 2023-11-23 Memorial Sloan Kettering Cancer Center Compositions targeting ndc80/mhc complexes and uses thereof
WO2022083668A1 (en) 2020-10-21 2022-04-28 Nanjing Legend Biotech Co., Ltd. Use of a chimeric co-stimulatory receptor for cell therapy
US20240000834A1 (en) 2020-11-24 2024-01-04 Shanghai GenBase Biotechnology Co., Ltd. Ras mutant epitope peptide and t cell receptor recognizing ras mutant
AU2021408160A1 (en) 2020-12-21 2023-06-29 Zymeworks Bc Inc. Stabilized tcr constructs and methods of use
US12234473B2 (en) 2020-12-31 2025-02-25 Immatics US, Inc. CD8 polypeptides, compositions, and methods of using thereof
US20240327490A1 (en) 2021-01-08 2024-10-03 The Johns Hopkins University Sars-cov-2-specific t cell receptors and related materials and methods of use
AU2022224066A1 (en) 2021-02-19 2023-09-07 Angeles Therapeutics, Inc. Single-chain and multi-chain synthetic antigen receptors for diverse immune cells
EP4423116A4 (en) 2021-10-25 2025-12-17 Univ California METHODS AND COMPOSITIONS FOR THE TREATMENT OF GLIOBLASTOM
WO2023139289A1 (en) 2022-01-24 2023-07-27 Eth Zurich Universal tcr variants for allogeneic immunotherapy
WO2023173024A2 (en) 2022-03-10 2023-09-14 The Board Of Trustees Of The Leland Stanford Junior University Treatment of coronary artery disease by reducing activity of cross-reactive t cells

Also Published As

Publication number Publication date
US20240092933A1 (en) 2024-03-21
TW202309071A (zh) 2023-03-01
US11859009B2 (en) 2024-01-02
CA3217738A1 (en) 2022-05-04
BR112023022765A2 (pt) 2024-01-02
US12570760B2 (en) 2026-03-10
AU2022270361A1 (en) 2023-11-16
US20230091330A1 (en) 2023-03-23
KR20240004935A (ko) 2024-01-11
PE20242343A1 (es) 2024-12-16
IL308257A (en) 2024-01-01
US20230357428A1 (en) 2023-11-09
US20220372165A1 (en) 2022-11-24
JP2024518378A (ja) 2024-05-01
CL2023003232A1 (es) 2024-04-19
WO2022233956A1 (en) 2022-11-10
EP4334361A1 (en) 2024-03-13
CO2023014722A2 (es) 2024-02-05

Similar Documents

Publication Publication Date Title
MX2022011411A (es) Proteinas de union a antigeno que se unen especificamente a mage-a.
MX2023012902A (es) Proteinas de union a antigenos que se unen especificamente a prame.
PH12020550600A1 (en) Novel engineered t cell receptors and immune therapy using the same
PH12019502847A1 (en) Novel t cell receptors and immune therapy using the same
PH12019502151A1 (en) T cell receptors and immune therapy using the same against prame positive cancers
EA201892021A1 (ru) Трансфицированные t-клетки и t-клеточные рецепторы для применения в иммунотерапии раковых заболеваний
EA201891759A1 (ru) Трансфицированные t-клетки и t-клеточные рецепторы для применения в иммунотерапии раковых заболеваний
RU2014120536A (ru) Белки специфического связывания и их применения
CN116731156A (zh) 用于癌症免疫治疗的转染t细胞和t细胞受体
DE502005009602D1 (de) Identifizierung von oberflächen-assoziierten antigenen für die tumordiagnose und -therapie
JP2018509163A5 (es)
TW201217525A (en) Method for activating helper T cells
CA2884366A1 (en) Antigen-specific helper t-cell receptor genes
WO2021022447A1 (zh) 识别afp抗原短肽的t细胞受体
KR20180119605A (ko) ＨＬＡ-Ｂ５７ 개방 이형태체(open conformer)
AU2009232774B2 (en) Partial peptide of Survivin presented on MHC class II molecule and use thereof
TW202140532A (zh) 一種辨識afp的t細胞受體及其編碼序列
NZ750479A (en) T cell receptors and immune therapy using the same
EA202190572A1 (ru) Иммунотерапия раковых заболеваний рестриктированными по a*01 пептидами и комбинациями пептидов и относящиеся к ней способы
AR125763A1 (es) Proteínas de unión a antígenos que se unen específicamente a prame
MX2025013106A (es) Anticuerpos dirigidos al complejo peptidico de catepsina g del antigeno leucocitario humano
MX2024001179A (es) Proteinas de union a antigenos que se unen especificamente a ct45.
PH12019501263A1 (en) Novel t cell receptors and immune therapy using the same
CN119798408A (zh) 一种识别hpv多抗原表位的tcr及其编码序列
EA202191411A1 (ru) Иммунотерапия раковых заболеваний рестриктированными по b*08 пептидами и комбинациями пептидов и связанные с ними способы